The Prognostic Impact of Cytogenetic Scores in Patients with Higher-Risk Myelodysplastic Syndrome Treated with Venetoclax and Azacitidine in a Phase 1 Study

被引：0

作者：

Garcia, Jacqueline S. ^{[1
]}

Wei, Andrew H. ^{[2
,3
]}

Borate, Uma ^{[4
]}

Fong, Chun Yew ^{[5
]}

Baer, Maria R. ^{[6
]}

Nolte, Florian ^{[7
]}

Peterlin, Pierre ^{[8
]}

Jurcic, Joseph ^{[9
]}

Jacoby, Meagan ^{[10
,11
]}

Hong, Wen-Jen ^{[12
]}

Platzbecker, Uwe ^{[13
]}

Odenike, Olatoyosi ^{[14
,15
]}

Cunningham, Ilona ^{[16
]}

Zhou, Ying ^{[17
]}

Dunbar, Martin ^{[17
]}

Harb, Jason G. ^{[17
]}

Popovic, Relja ^{[17
]}

Tanwani, Poonam ^{[17
]}

Gopalakrishnan, Sathej ^{[18
]}

Wolff, Johannes ^{[17
]}

Garcia-Manero, Guillermo ^{[19
]}

机构：

[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA

[2] Alfred Hosp, Dept Haematol, Melbourne, Vic, Australia

[3] Monash Univ, Melbourne, Vic, Australia

[4] Oregon Hlth & Sci Univ, Knight Canc Inst, Div Hematol & Med Oncol, Portland, OR 97201 USA

[5] Austin Hlth, Olivia Newton John Canc Res Inst, Melbourne, Vic, Australia

[6] Univ Maryland, Sch Med, Greenebaum Comprehens Canc Ctr, Baltimore, MD 21201 USA

[7] Charite, Dept Hematol & Oncol, Campus Benjamin Franklin, Berlin, Germany

[8] Nantes Univ Hosp, Hematol Dept, Nantes, France

[9] Columbia Univ, Med Ctr, Myelodysplast Syndromes Ctr, New York, NY USA

[10] Barnes Jewish Hosp, Siteman Canc Ctr, St Louis, MO 63110 USA

[11] Washington Univ, Sch Med, St Louis, MO USA

[12] Genentech Inc, San Francisco, CA 94080 USA

[13] Univ Hosp Leipzig, Med Clin & Policlin 1, Hematol & Cellular Therapy, Leipzig, Germany

[14] Univ Chicago Med, Chicago, IL USA

[15] Comprehens Canc Ctr, Chicago, IL USA

[16] Univ Sydney, Concord Clin Sch, Sydney, NSW, Australia

[17] AbbVie Inc, N Chicago, IL USA

[18] AbbVie Deutschland GmbH & Co KG, Wiesbaden, Germany

[19] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2020年 / 20卷

关键词：

BCL-2; inhibitor; combination therapy; higher-risk MDS; efficacy; MDS; myelodysplastic syndromes;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MDS-141

引用

页码：S315 / S316

页数：2

共 50 条

[21] Prognostic significance of monosomal karyotype in higher risk myelodysplastic syndrome treated with azacitidine
Itzykson, R.
Thepot, S.
Eclache, V.
Quesnel, B.
Dreyfus, F.
Beyne-Rauzy, O.
Turlure, P.
Vey, N.
Recher, C.
Boehrer, S.
Gardin, C.
Ades, L.
Fenaux, P.
LEUKEMIA, 2011, 25 (07) : 1207 - 1209
[22] Prognostic significance of monosomal karyotype in higher risk myelodysplastic syndrome treated with azacitidine
R Itzykson
S Thépot
V Eclache
B Quesnel
F Dreyfus
O Beyne-Rauzy
P Turlure
N Vey
C Recher
S Boehrer
C Gardin
L Adès
P Fenaux
Leukemia, 2011, 25 : 1207 - 1209
[23] Phase I Combination Trial of Lenalidomide and Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes
Sekeres, Mikkael A.
List, Alan F.
Cuthbertson, David
Paquette, Ronald
Ganetsky, Rebecca
Latham, Deborah
Paulic, Katarina
Afable, Manuel
Saba, Hussain I.
Loughran, Thomas P., Jr.
Maciejewski, Jaroslaw P.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (13) : 2253 - 2258
[24] Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study
Sallman, David A.
Al Malki, Monzr M.
Asch, Adam S.
Wang, Eunice S.
Jurcic, Joseph G.
Bradley, Terrence J.
Flinn, Ian W.
Pollyea, Daniel A.
Kambhampati, Suman
Tanaka, Tiffany N.
Zeidner, Joshua F.
Garcia-Manero, Guillermo
Jeyakumar, Deepa
Komrokji, Rami
Lancet, Jeffrey
Kantarjian, Hagop M.
Gu, Lin
Zhang, Yajia
Tan, Anderson
Chao, Mark
O'Hear, Carol
Ramsingh, Giridharan
Lal, Indu
Vyas, Paresh
Daver, Naval G.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (15) : 2815 - +
[25] Efficacy and Safety of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Treatment-Naive, Higher-Risk Myelodysplastic Syndromes
Garcia, Jacqueline S.
Platzbecker, Uwe
Odenike, Olatoyosi
Fleming, Shaun
Fong, Chun Yew
Cook, Rachel
Jacoby, Meagan
Nowak, Daniel
Chyla, Brenda
Zhou, Ying
Ku, Grace
Potluri, Jalaja
Garcia-Manero, Guillermo
BLOOD, 2023, 142
[26] A phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes
Mikkael A. Sekeres
Michael Schuster
Magalie Joris
Jürgen Krauter
Johan Maertens
Dimitri Breems
Emmanuel Gyan
Tibor Kovacsovics
Amit Verma
Paresh Vyas
Eunice S. Wang
Keith Ching
Thomas O’Brien
Corrado Gallo Stampino
Weidong Wendy Ma
Arthur Kudla
Geoffrey Chan
Amer M. Zeidan
Annals of Hematology, 2022, 101 : 1689 - 1701
[27] Updated Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Previously-Untreated Patients with Higher-Risk Myelodysplastic Syndrome
Chien, Kelly S.
Borthakur, Gautam
Naqvi, Kiran
Daver, Naval
Bravo, Guillermo Montalban
Cortes, Jorge E.
DiNardo, Courtney D.
Jabbour, Elias
Alvarado, Yesid
Andreeff, Michael
Bose, Prithviraj
Jain, Nitin
Sheppard, Kimberly
Klingner-Winton, Cheri
Pierce, Sherry A.
Dong, Xiao Qin
Soltysiak, Kelly A.
Kantarjian, Hagop M.
Garcia-Manero, Guillermo
BLOOD, 2020, 136
[28] Updated Safety and Efficacy of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Treatment-Naive, Higher-Risk Myelodysplastic Syndromes: Phase 1b Results
Wei, Andrew H.
Garcia, Jacqueline S.
Borate, Uma
Fong, Chun Yew
Baer, Maria R.
Nowak, Daniel
Peterlin, Pierre
Jurcic, Joseph
Jacoby, Meagan A.
Platzbecker, Uwe
Odenike, Olatoyosi
Cunningham, Ilona
Zhou, Ying
Hoffman, David
Hogdal, Leah
Naqvi, Kiran
Kye, Steve
Garcia-Manero, Guillermo
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S343 - S343
[29] Predicting the outcome of patients with higher-risk myelodysplastic syndrome treated with hypomethylating agents
Itzykson, Raphael
Fenaux, Pierre
LEUKEMIA & LYMPHOMA, 2012, 53 (05) : 760 - 762
[30] Impact of cytogenetic abnormalities on response to azacitidine in patients with myelodysplastic syndrome
Iizuka, Hiroko
Sugimoto, Keiji
Takizawa, Haruko
Wakabayashi, Mutsumi
Sakajiri, Sakura
Sekiguchi, Yasunobu
Noguchi, Masaaki
Komatsu, Norio
ANNALS OF ONCOLOGY, 2019, 30

← 1 2 3 4 5 →